Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma

Pedro H enrique Isaacsson Velho, Gilberto Castro, Christine H. Chung

Research output: Contribution to journalReview article

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal epithelia in the head and neck region. The most common risk factors are tobacco use, alcohol consumption, and HPV infection, particularly in the oropharynx. The HPV-positive HNSCC is biologically and clinically distinct from the HPV-negative HNSCC; however, deregulations within the phosphatidylinositol 3-kinase (PI3K) pathway are frequent in both HPV-positive and HPV-negative HNSCC as it is the most frequently altered oncogenic pathway with a gain-of-function in HNSCC. This article reviews the basic biology and clinical data from the trials involving anticancer agents targeting the PI3K pathway in HNSCC. It also discusses the difficulties of translating the preclinical data to tangible clinical efficacy of these agents in patients with HNSCC even when there is significant preclinical data suggesting the PI3K pathway is a promising therapeutic target in HNSCC. We conclude that additional studies to determine appropriate patient selection for the activation of PI3K pathway and to develop targeted agents either as a monotherapy or combination therapy with favorable toxicity profiles are required before a broader clinical application.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalAmerican Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Oropharynx
Carcinoma, squamous cell of head and neck
Tobacco Use
Proxy
Alcohol Drinking
Antineoplastic Agents
Patient Selection
Neck
Epithelium
Head
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma. / Isaacsson Velho, Pedro H enrique; Castro, Gilberto; Chung, Christine H.

In: American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2015, p. 123-128.

Research output: Contribution to journalReview article

@article{8c2ed7f6931e47ef8baa613546e953a2,
title = "Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma",
abstract = "Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal epithelia in the head and neck region. The most common risk factors are tobacco use, alcohol consumption, and HPV infection, particularly in the oropharynx. The HPV-positive HNSCC is biologically and clinically distinct from the HPV-negative HNSCC; however, deregulations within the phosphatidylinositol 3-kinase (PI3K) pathway are frequent in both HPV-positive and HPV-negative HNSCC as it is the most frequently altered oncogenic pathway with a gain-of-function in HNSCC. This article reviews the basic biology and clinical data from the trials involving anticancer agents targeting the PI3K pathway in HNSCC. It also discusses the difficulties of translating the preclinical data to tangible clinical efficacy of these agents in patients with HNSCC even when there is significant preclinical data suggesting the PI3K pathway is a promising therapeutic target in HNSCC. We conclude that additional studies to determine appropriate patient selection for the activation of PI3K pathway and to develop targeted agents either as a monotherapy or combination therapy with favorable toxicity profiles are required before a broader clinical application.",
author = "{Isaacsson Velho}, {Pedro H enrique} and Gilberto Castro and Chung, {Christine H.}",
year = "2015",
doi = "10.14694/EdBook_AM.2015.35.123",
language = "English (US)",
pages = "123--128",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma

AU - Isaacsson Velho, Pedro H enrique

AU - Castro, Gilberto

AU - Chung, Christine H.

PY - 2015

Y1 - 2015

N2 - Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal epithelia in the head and neck region. The most common risk factors are tobacco use, alcohol consumption, and HPV infection, particularly in the oropharynx. The HPV-positive HNSCC is biologically and clinically distinct from the HPV-negative HNSCC; however, deregulations within the phosphatidylinositol 3-kinase (PI3K) pathway are frequent in both HPV-positive and HPV-negative HNSCC as it is the most frequently altered oncogenic pathway with a gain-of-function in HNSCC. This article reviews the basic biology and clinical data from the trials involving anticancer agents targeting the PI3K pathway in HNSCC. It also discusses the difficulties of translating the preclinical data to tangible clinical efficacy of these agents in patients with HNSCC even when there is significant preclinical data suggesting the PI3K pathway is a promising therapeutic target in HNSCC. We conclude that additional studies to determine appropriate patient selection for the activation of PI3K pathway and to develop targeted agents either as a monotherapy or combination therapy with favorable toxicity profiles are required before a broader clinical application.

AB - Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal epithelia in the head and neck region. The most common risk factors are tobacco use, alcohol consumption, and HPV infection, particularly in the oropharynx. The HPV-positive HNSCC is biologically and clinically distinct from the HPV-negative HNSCC; however, deregulations within the phosphatidylinositol 3-kinase (PI3K) pathway are frequent in both HPV-positive and HPV-negative HNSCC as it is the most frequently altered oncogenic pathway with a gain-of-function in HNSCC. This article reviews the basic biology and clinical data from the trials involving anticancer agents targeting the PI3K pathway in HNSCC. It also discusses the difficulties of translating the preclinical data to tangible clinical efficacy of these agents in patients with HNSCC even when there is significant preclinical data suggesting the PI3K pathway is a promising therapeutic target in HNSCC. We conclude that additional studies to determine appropriate patient selection for the activation of PI3K pathway and to develop targeted agents either as a monotherapy or combination therapy with favorable toxicity profiles are required before a broader clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85003052214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003052214&partnerID=8YFLogxK

U2 - 10.14694/EdBook_AM.2015.35.123

DO - 10.14694/EdBook_AM.2015.35.123

M3 - Review article

SP - 123

EP - 128

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -